Abstract
Syndromic retinitis pigmentosa (RP) is the result of several mutations expressed in rod photoreceptors, over 40 of which have so far been identified. Enormous efforts are being made to relate the advances in unraveling the pathophysiological mechanisms to therapeutic approaches in animal models, and eventually in clinical trials on humans. This review summarizes briefly the current clinical management of RP and focuses on the new exciting treatment possibilities. To date, there is no approved therapy able to stop the evolution of RP or restore vision. The current management includes an attempt at slowing down the degenerative process by vitamin supplementation, trying to treat ocular complications and to provide psychological support to blind patients. Novel therapeutic may be tailored dependant on the stage of the disease and can be divided in three groups. In the early stages, when there are surviving photoreceptors, the first approach would be to try to halt the degeneration by correction of the underlying biochemical abnormality in the visual cycle using gene therapy or pharmacological treatment. A second approach aims to cope with photoreceptor cell death using neurotrophic growth factors or anti-apoptotic factors, reducing the production of retino-toxic molecules, and limiting oxidative damage. In advanced stages, when there are few or no functional photoreceptors, strategies that may benefit include retinal transplantation, electronic retinal implants or a newly described optogenetic technique using a light-activated channel to genetically resensitize remnant cone-photoreceptor cells.
Keywords: Calpain Inhibitors, Apoptosis, macular edema, phagocytosis, treatment, retinitis pigmentosa, retinal transplant, retinal prosthesis, neuroprotection, Gene therapy
Current Genomics
Title: Therapeutic Challenges to Retinitis Pigmentosa: From Neuroprotection to Gene Therapy
Volume: 12 Issue: 4
Author(s): Jayashree N. Sahni, Martina Angi, Cristina Irigoyen, Martina Angi, Francesco Semeraro, Mario R. Romano, Francesco Parmeggiani and Francesco Parmeggiani
Affiliation:
Keywords: Calpain Inhibitors, Apoptosis, macular edema, phagocytosis, treatment, retinitis pigmentosa, retinal transplant, retinal prosthesis, neuroprotection, Gene therapy
Abstract: Syndromic retinitis pigmentosa (RP) is the result of several mutations expressed in rod photoreceptors, over 40 of which have so far been identified. Enormous efforts are being made to relate the advances in unraveling the pathophysiological mechanisms to therapeutic approaches in animal models, and eventually in clinical trials on humans. This review summarizes briefly the current clinical management of RP and focuses on the new exciting treatment possibilities. To date, there is no approved therapy able to stop the evolution of RP or restore vision. The current management includes an attempt at slowing down the degenerative process by vitamin supplementation, trying to treat ocular complications and to provide psychological support to blind patients. Novel therapeutic may be tailored dependant on the stage of the disease and can be divided in three groups. In the early stages, when there are surviving photoreceptors, the first approach would be to try to halt the degeneration by correction of the underlying biochemical abnormality in the visual cycle using gene therapy or pharmacological treatment. A second approach aims to cope with photoreceptor cell death using neurotrophic growth factors or anti-apoptotic factors, reducing the production of retino-toxic molecules, and limiting oxidative damage. In advanced stages, when there are few or no functional photoreceptors, strategies that may benefit include retinal transplantation, electronic retinal implants or a newly described optogenetic technique using a light-activated channel to genetically resensitize remnant cone-photoreceptor cells.
Export Options
About this article
Cite this article as:
N. Sahni Jayashree, Angi Martina, Irigoyen Cristina, Angi Martina, Semeraro Francesco, R. Romano Mario, Parmeggiani Francesco and Parmeggiani Francesco, Therapeutic Challenges to Retinitis Pigmentosa: From Neuroprotection to Gene Therapy, Current Genomics 2011; 12 (4) . https://dx.doi.org/10.2174/138920211795860062
DOI https://dx.doi.org/10.2174/138920211795860062 |
Print ISSN 1389-2029 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5488 |
Call for Papers in Thematic Issues
Advanced Computational Algorithms and Artificial Intelligence in Clinical Pharmacogenomics
In the era of personalized medicine, understanding the relationship between genetics and drug response is crucial. This issue delves into innovative methodologies, leveraging deep computational analysis and artificial intelligence, to enhance the field of Clinical Pharmacogenomics. The interdisciplinary approach harnesses the power of advanced high-throughput genotyping technologies, sophisticated computational analysis, ...read more
Applications of Single-cell Sequencing Technology in Reproductive Medicine
Single cell sequencing (SCS) technology utilizes individual cells' genetic material to sequence their genome, transcriptome, and epigenetics at the molecular level. It offers insights into cell heterogeneity and enables the study of limited biological materials. Since its recognition as a valuable technique in 2011, single cell sequencing has yielded numerous ...read more
Big Data in Cancer Research
Cancer is a significant threat to human life and health, remaining a highly aggressive killer. It is a leading cause of death worldwide and represents a crucial medical issue for humanity. However, in the past decade, the effectiveness of new synthetic anticancer agents has not matched the current clinical speculation. ...read more
Current Genomics in Cardiovascular Research
Cardiovascular diseases are the main cause of death in the world, in recent years we have had important advances in the interaction between cardiovascular disease and genomics. In this Research Topic, we intend for researchers to present their results with a focus on basic, translational and clinical investigations associated with ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Underlying Role of Oxidative Stress in Neurodegeneration: A Mechanistic Review
CNS & Neurological Disorders - Drug Targets Expression and Function of the Endocannabinoid System in Glial Cells
Current Pharmaceutical Design CHIP Knockdown Reduced Heat Shock Response and Protein Quality Control Capacity in Lens Epithelial Cells
Current Molecular Medicine Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility
Current Medicinal Chemistry Medicinal Plants: A Natural Chaperones Source for Treating Neurological Disorders
Protein & Peptide Letters Alzheimer´s Disease and Oxidative Stress: A Review
Current Medicinal Chemistry Recent Advances in Obesity Pharmacotherapy
Current Clinical Pharmacology Inflammatory Process in Alzheimer’s and Parkinson's Diseases: Central Role of Cytokines
Current Pharmaceutical Design Subject Index to Volume 9
Current Pharmaceutical Design NMDA Receptor Antagonists as Antidepressant and Antidementia Drugs: Recent Developments and Future Prospects
Current Medicinal Chemistry - Central Nervous System Agents Antioxidant Activity of Galantamine and Some of its Derivatives
Current Medicinal Chemistry Immunological Approaches to Prevent Neuronal Apoptosis During Neuroinflammation
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Molecular Genetics of Early- and Late-Onset Alzheimer’s Disease
Current Gene Therapy Pharmaceutical Targeting of the Brain
Current Pharmaceutical Design Pharmacophore, Similarity and ADMET Screening of Casein Kinase 1 inhibitors in Alzheimer's Disease
Current Bioactive Compounds Prostaglandins and Cyclooxygenases in Glial Cells During Brain Inflammation
Current Drug Targets - Inflammation & Allergy Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy
Current Pharmaceutical Design Editorial [Hot Topic: Animal Models for Neurodegenerative Diseases Associated to Accumulation of Misfolded Protein Aggregates (Executive Guest Editor: Claudio Soto)]
Current Pharmaceutical Design Antioxidant Enzyme Mimics with Synergism
Mini-Reviews in Medicinal Chemistry Group I Metabotropic Glutamate Receptor Signalling and its Implication in Neurological Disease
CNS & Neurological Disorders - Drug Targets